CDMO Strength Peregrine operates Avid Bioservices, a wholly-owned CDMO with in-house cGMP manufacturing capabilities, presenting a turnkey opportunity for partners seeking scalable biologics development and manufacturing services for cancer therapies.

Immunotherapy Focus Lead program bavituximab in multiple cancer indications, including second-line NSCLC and frontline settings, signaling high-value collaboration potential in oncology with an emphasis on monoclonal antibody therapies and related diagnostic imaging agents.

Clinical Momentum Active and upcoming clinical programs across diverse solid tumors suggest opportunities for companion diagnostics, translational biology collaborations, and potential co-development deals to expand indication footprints.

Strategic Partnerships Board and leadership stability with experienced CDMO leadership and recent executive appointments indicate a readiness for strategic partnerships, outsourcing deals, or licensing arrangements to accelerate development timelines.

Market Positioning Smaller biotech with mid-range revenue and a scalable manufacturing footprint positions Peregrine as a potential client or partner for specialized biotech providers seeking capacity, expertise, and differentiated oncology manufacturing solutions.